State Drug Administration approves Gilead Xia Fanning ® to treat chronic hepatitis C virus infection in China
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
chronic hepatitis C is a major public health challenge worldwideIn China, nearly 10 million people are infected with hCV, of which about 58% are HCV-type 1 patientsrecently, Gilead Sciences (NASDAQ: GILD) announced that China's NationalDrug(http://Regulatory Authority has approved xia Fanning ® (Getty Paiway 90mg/Sophobuvir 400mg) for the treatment of adults and adolescents aged 12 to 18 with chronic hepatitis 1 virus (HCV) infection in Chinathe approval of Xia Fanning ®
Xia Fanning ® This approval is based on an open label phase 3b study conducted in 18 research centers in Chinese mainland from May 2016 to July 2017, assessing the effectiveness of® 12 weeks of treatment in 206 patients with gene type 1 hepatitis C in 206 cases of Gene 1 hepatitis C patients, including those without treatment and those without liver cirrhosis or with intricosised liver cirrhosisin the study, 100% of the enrolled patients achieved SVR12The most common adverse reactions in patients are viral upper respiratory tract infections and upper respiratory tract infections
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
